Journal of Medicinal Chemistry · 2002 · 138 citations · 32 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsEnzyme InhibitionLead Compound DesignLigand BindingLigand-based DesignStructure-activity Relationship AnalysisAnticancer ActivityAnticancer ChemotherapyParp InhibitionPhysical PropertiesPoly Adp-ribose Polymerase InhibitorsPoly(adp-ribose) Polymerase 1Poly(adp-ribose) Polymerase InhibitionPoly(adp-ribose) Polymerase Inhibitors
A series of novel compounds have been designed that are potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1), and the activity and physical properties have been characterized. The new structural classes, 3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-6-ones and 3,4-dihydropyrrolo[4,3,2-de]isoquinolin-5-(1H)-ones, have conformationally locked benzamide cores that specifically interact with the PARP-1 protein. The compounds have been evaluated with in vitro cellular assays that measure the ability of the PARP-1 inhibitors to enhance the effect of cytotoxic agents against cancer cell lines.
32
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
Damien D’Amours, Serge Desnoyers, Icy D’Silva et al. · Biochemical Journal · 1999 · 1.8K citations · Full text
(ADP-ribose)n participates in DNA excision repair
Barbara W. Durkacz, Olusesan Omidiji, Douglas A. Gray et al. · Nature · 1980 · 1.1K citations
Novel inhibitors of poly(ADP-ribose) synthetase
Michael R. Purnell, WILLIAM J. D. WHISH · Biochemical Journal · 1980 · 529 citations · Full text